

Customer No. 28880

Confirmation No. 4097

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages In This Submission


8

Application Number	10/801,897
Filing Date	March 15, 2004
First Named Inventor	Dasseux, et al
Art Unit	1654
Examiner Name	Jeffrey E. Russel
Attorney Docket Number	9196-032-999/PC20701C

**RECEIVED****CENTRAL FAX CENTER****MAR 10 2006****ENCLOSURES (Check all that apply)**


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer (3) <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> Remarks Authorization to charge the fee and any additional fees as necessary or credit any overpayment to deposit account 23-0455 is hereby given.
<input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Pfizer Inc.		
Signature			
Printed name	Martha A. Gammill		
Date	March 10, 2006	Reg. No.	31,820

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	
Typed or printed name	Nancy Dembach
Date	March 10, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

USPTO Fax No. 571-273-8300

9196-032-999 (PC20701C)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED  
CENTRAL FAX CENTER**

Application No.: 10/801,897

**MAR 10 2006**

Applicant: Jean-Louis Dasseux

Filed: March 15, 2004

TC/A.U.: 1654

Examiner: Jeffrey E. Russel

Docket No.: 9196-032-999 (PC20701C)

Customer No.: 28880

For: Apolipoprotein A-I Agonists and Their Use to Treat Dyslipidemic Disorders

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO NOTICE OF NON-COMPLIANT  
AMENDMENT (37 C.F.R. 1.121)**

Dear Sir/Madam:

This paper is in response to the Notice of Non-Compliant Amendment (37 C.F.R. 1.121) dated February 10, 2006. In the Notice of Non-Compliant Amendment, it is noted that the Amendment filed on February 3, 2006 is non-compliant because a complete listing of all the claims was not present.


Enclosed with this paper, Applicants submit a complete listing of claims, including deleted claims 1-52, which were inadvertently omitted in the Reply and Amendment under 37 C.F.R. § 1.111 and 1.121, filed on February 3, 2006.

The requirement of a submission of a complete listing of claims has now been met. Accordingly, Applicants respectfully request acceptance of the above-identified Amendment filed on February 3, 2006.

Authorization is hereby given to charge any fee which may be required to Deposit Account 23-0455.

Applicant respectfully requests examination of the application on the merits.

Respectfully submitted,



Martha A. Gammill  
Registration No. 31, 820  
Pfizer, Inc.  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Tel. (734) 622-5940  
Fax (734) 622-1553